Global mRNA Vaccines & Therapeutics Market Insights and Forecast to 2028

mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
Market Analysis and Insights: Global mRNA Vaccines & Therapeutics Market
Due to the COVID-19 pandemic, the global mRNA Vaccines & Therapeutics market size is estimated to be worth US$ 3894 million in 2022 and is forecast to a readjusted size of US$ 1575.4 million by 2028 with a CAGR of -14.0% during the review period. Fully considering the economic change by this health crisis, Infectious Disease Vaccines accounting for % of the mRNA Vaccines & Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Infectious Disease segment is altered to an % CAGR throughout this forecast period.
Global core mRNA vaccines & therapeutics manufacturers include Moderna Therapeutics, CureVac etc. The top 3 companies hold a share about 65%. Europe is the largest market, with a share about 10%, followed by Asia Pacific and North America.
Global mRNA Vaccines & Therapeutics Scope and Segment
mRNA Vaccines & Therapeutics market is segmented by Type and by Application. Players, stakeholders, and other participants in the global mRNA Vaccines & Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
Segment by Application
Infectious Disease
Cancer
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE